carlumab
mAbexperimental
Carlumab is a discontinued human recombinant monoclonal antibody that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00537368)
Timeline
Indications
Mechanism of action
- C-C motif chemokine 2INHIBITOR
CCL2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCarlumab ↗
- ChEMBLCHEMBL1742999 ↗
Also known as
- carlumab
- carlumab
- carlumab
- carlumab
- cnto888
- cnto 888
- cnto 888
- cnto-888
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01204996 | Phase 1 | May 1, 2010 | Centocor |
| NCT00992186 | Phase 2 | Sep 1, 2009 | Centocor |
| NCT00786201 | Phase 2 | Dec 1, 2008 | Centocor |
| NCT00537368 | Phase 1 | Sep 1, 2007 | Centocor |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Centocor | For profit | 4 | 4 | 2 | 2007 |
1 organizations
Page 1 / 1